Neurology

5 drugs are in development for Alzheimer Disease.

Companies: 5
Clinical trials: 78

BioSniper AIPage evidence connected

Prepared research question

Which programs lead the Alzheimer Disease pipeline—and what evidence could change the picture?

Run cited research

Traceable citations · Unknowns marked

Drug Pipeline by Phase

Phase 3(1)

Drug	Company
AXS-05	Axsome Therapeutics, Inc. (AXSM)

Phase 2(1)

Drug	Company
igc-ad1	IGC Pharma, Inc. (IGC)

Phase 1(1)

Drug	Company
lx1001	Lexeo Therapeutics, Inc. (LXEO)

Phase 1/Phase 2(1)

Drug	Company
ALZN002	Alzamend Neuro, Inc. (ALZN)

Phase 4(1)

Drug	Company
zunveyl	Alpha Cognition Inc. (ACOG)

About this indication

Alzheimer Disease context

Neurology·MeSH: Alzheimer Disease (D000544)

Also known as: Alzheimer Dementias, Alzheimer Diseases, Alzheimer Syndrome, Alzheimer Type Dementia, Alzheimer's Disease, Alzheimers Diseases, Dementia, Alzheimer, Primary Senile Degenerative Dementia, Sclerosis, Alzheimer, Senile Dementia, Senile Dementia, Alzheimer Type

Narrower concepts tracked separately: Alzheimer Disease, Early Onset

Prevalence

700.0 / 100K

Incidence

120.0 / 100K/yr

Frequently asked questions

How many drugs are in development for Alzheimer Disease?

BioSniper tracks 5 drugs in development for Alzheimer Disease across 5 companies.

How many clinical trials target Alzheimer Disease?

There are 78 clinical trials targeting Alzheimer Disease tracked by BioSniper.

What is the prevalence of Alzheimer Disease?

The estimated prevalence of Alzheimer Disease is approximately 700.0 per 100,000 population.